Black Rock Inc. Intercept Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$9.99 - $18.71 $1.84 Million - $3.45 Million	-184,150 Reduced 4.19%	4,212,820 $78.1 Million
Q2 2023 Aug 11, 2023	BUY	$9.17 - $19.29 $12.3 Million - $25.8 Million	1,338,026 Added 43.74%	4,396,970 $48.6 Million
Q1 2023 May 12, 2023	SELL	$12.53 - $21.71 $324,389 - $562,050	-25,889 Reduced 0.84%	3,058,944 $41.1 Million
Q4 2022 Feb 13, 2023	BUY	$11.61 - $16.11 $1.73 Million - $2.39 Million	148,646 Added 5.06%	3,084,833 $38.2 Million
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $2.66 Million - $4.29 Million	217,833 Added 8.01%	2,936,187 $41 Million
Q2 2022 Aug 12, 2022	BUY	$11.23 - $19.59 $708,579 - $1.24 Million	63,097 Added 2.38%	2,718,354 $37.5 Million
Q1 2022 May 12, 2022	BUY	$13.37 - $17.79 $5.66 Million - $7.53 Million	423,165 Added 18.96%	2,655,257 $43.2 Million
Q4 2021 Feb 10, 2022	SELL	$14.28 - $19.53 $1.88 Million - $2.57 Million	-131,371 Reduced 5.56%	2,232,092 $36.4 Million
Q3 2021 Nov 09, 2021	BUY	$12.99 - $20.47 $250,771 - $395,173	19,305 Added 0.82%	2,363,463 $35.1 Million
Q2 2021 Aug 11, 2021	BUY	$15.46 - $24.5 $36.2 Million - $57.4 Million	2,344,158 New	2,344,158 $46.8 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.